KDM1A and esophageal squamous cell carcinoma: Overall, our in vitro and in vivo data from multiple ESCC models sufficiently confirmed the oncogenic roles of KDM1A in ESCC, suggesting that its inhibitors are promising for improving the outcomes of patients with early staged ESCC with high KDM1A expression.